Connect Biopharma (CNTB) vs LeonaBio (LONA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
LeonaBio (LONA) has outperformed Connect Biopharma (CNTB) over the past year, gaining 45.9% versus a loss of 51.6%. Over five years, LONA leads with a -94.0% price change compared with -94.9% for CNTB. Connect Biopharma is the larger company by market cap ($55.5 million vs $54.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTB | LONA |
|---|---|---|
| Share price | $0.8807 | $5.75 |
| Market cap | $55.46M | $54.17M |
| 1-day change | -6.77% | -1.37% |
| YTD return | -68.77% | -24.04% |
| 1-year return | -51.61% | +45.94% |
| 5-year return | -94.87% | -93.99% |
| EPS (TTM) | $-1.19 | $-23.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.82 | $14.21 |
| 52-week low | $0.85 | $2.21 |
| Distance from 52-week high | -76.95% | -59.54% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +567.65% | +201.39% |
| Average volume | 3.81M | 185.45K |
| Shares outstanding | 62.97M | 9.42M |
| Employees | 64 | 19 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LONA has outperformed CNTB by 97.5 percentage points over the past year.
About Connect Biopharma
CNTB stock →Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
Healthcare · Biotechnology · 64 employees
About LeonaBio
LONA stock →LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Healthcare · Biotechnology · 19 employees
CNTB vs LONA FAQ
Which is bigger, Connect Biopharma or LeonaBio?
Connect Biopharma (CNTB) is larger, with a market capitalization of $55.46M compared with $54.17M for LeonaBio (LONA).
Which stock has performed better over the past year, CNTB or LONA?
LONA returned +45.94% over the past 12 months, compared with -51.61% for CNTB (price return, excluding dividends). Past performance does not predict future results.
Are Connect Biopharma and LeonaBio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.